PHAT (Phathom Pharmaceuticals) Current Accrued Expense: $97.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAT Phathom Pharmaceuticals Inc PHAT
38 GF Score
Price $9.19
GF Value $25.26
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Current Accrued Expense?

Phathom Pharmaceuticals PHAT +2.74% 38 Current Accrued Expense is $97.2 Mil as of Jun. 2026. GuruFocus rates PHAT with a GF Score™ of 38/100 and a GF Value™ of $25.26 (Possible Value Trap). The stock has 2 warning signs investors should review.

Phathom Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $97.2 Mil.

Phathom Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($76.8 Mil) to Mar. 2026 ($75.8 Mil) but then increased from Mar. 2026 ($75.8 Mil) to Jun. 2026 ($97.2 Mil).

Phathom Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($5.0 Mil) to Dec. 2024 ($38.3 Mil) and increased from Dec. 2024 ($38.3 Mil) to Dec. 2025 ($76.8 Mil).

Phathom Pharmaceuticals Current Accrued Expense Related Terms

Phathom Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals Current Accrued Expense Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 6.94 7.09 5.03 38.28 76.82

Phathom Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.34 52.32 76.82 75.78 97.16
PHAT
38GF Score
Phathom Pharmaceuticals Inc PHAT
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $97.2 Mil mean?
Phathom Pharmaceuticals (PHAT) has a Current Accrued Expense of $97.2 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' Current Accrued Expense too high?
Phathom Pharmaceuticals' current Current Accrued Expense is $97.2 Mil. Overall, Phathom Pharmaceuticals has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Current Accrued Expense compare to GERN and KURA?
Phathom Pharmaceuticals' Current Accrued Expense of $97.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current Current Accrued Expense is $97.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Phathom Pharmaceuticals (PHAT) is currently considered Possible Value Trap. The stock's GF Value™ is $25.26, compared to a current price of $9.19 — trading 63.6% below its estimated fair value. The current Current Accrued Expense is $97.2 Mil. Phathom Pharmaceuticals' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Current Accrued Expense is $97.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phathom Pharmaceuticals (PHAT) Overvalued in 2026?

Based on GuruFocus' analysis, Phathom Pharmaceuticals stock appears to be undervalued. The current stock price of $9.19 is trading 63.6% below its estimated GF Value™ of $25.26. GuruFocus considers Phathom Pharmaceuticals to be Possible Value Trap.

Key valuation signals for PHAT:

  • Current Accrued Expense: $97.2 Mil
  • GF Value™: $25.26 vs. price of $9.19 (63.6% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the PHAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
38GF Score

Get the complete analysis for PHAT

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.19
Price
$25.26
GF Value